Company news

Share this article:

GlaxoSmithKline has inked a deal worth as much as $425 million to develop drugs for respiratory and cardiovascular disease with San Diego company Amira Pharmaceuticals. The deal will give GSK worldwide rights to develop, manufacture and sell experimental compounds including an experimental asthma treatment known as AM103, which has already has shown promise in early human trials. Amira could receive as much as $425 million in payments if it meets all of its development and regulatory milestones. It also will receive royalty payments on sales of any of its drugs.

Roska Healthcare Advertising has launched a new Web site at www.roskahealthcare.com offering visitors a virtual tour of the firm's people, clients and category experience.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.